Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Active moderate to severe rheumatoid arthritis of \>/= 6 months duration~* \>/=1 non-biologic DMARD and/or anti-TNF therapy at stable dose for \>/=8 weeks at any time prior to study treatment~* Inadequate clinical response to non-biologic DMARD or anti-TNF therapy~* Oral corticosteroids must be at stable dose for at least 25 out of 28 days prior to first dose of study drug~Exclusion Criteria:~* Pregnant or lactating women~* Major surgery (including joint surgery) within 8 weeks prior to screening or major surgery planned within 6 months of enrolment~* Rheumatic autoimmune disease other than RA~* Functional class IV (ACR classification)~* Prior history of or current joint disease other than RA~* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* Previous treatment with RoActemra/Actemra~* Known active current or history of recurrent infection~* History of or currently active primary or secondary immunodeficiency~* Active tuberculosis requiring treatment within the previous 3 years~* Positive for HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).